- FUJIFILM Holdings America has expanded the responsibilities of three Life Sciences Group leaders, including appointing Tomoyuki Hasegawa as CEO of FUJIFILM Biotechnologies California.
- The leadership changes are intended to strengthen the company’s cell therapy CDMO capabilities and support growth in iPSC technologies, regenerative medicine, and cell-based therapeutics.
FUJIFILM Holdings America Corporation has announced expanded leadership responsibilities for three executives within its Life Sciences Group as the company continues to develop its cell therapy and regenerative medicine businesses. The appointments affect FUJIFILM Biotechnologies California and FUJIFILM Cellular Dynamics, both of which operate within Fujifilm’s life sciences portfolio.
Tomoyuki Hasegawa has been appointed Chief Executive Officer of FUJIFILM Biotechnologies California, a CDMO focused on biologics and advanced therapies. He will continue serving as General Manager of Fujifilm Life Sciences Strategic Office and Chairman and Chief Executive Officer of FUJIFILM Cellular Dynamics. Hasegawa has been with Fujifilm for more than 25 years and recently oversaw the opening of FUJIFILM Cellular Dynamics’ new headquarters and induced pluripotent stem cell (iPSC) development and manufacturing facility in Madison, Wisconsin.
The company also announced that Delara Motlagh, currently Chief Operating Officer of FUJIFILM Cellular Dynamics, will assume the additional role of President. Since joining the company in 2025, Motlagh has overseen business strategy and operations across the company’s discovery research and cell therapy CDMO units. In addition, Hasegawa will work alongside newly appointed Chief Operating Officer David Bolish at FUJIFILM Biotechnologies California to strengthen Fujifilm’s cell therapy manufacturing capabilities.
“As one of Fujifilm’s most experienced leaders, Tom, is positioned to align our cell therapy offerings across two complementary businesses, thus supporting a truly robust end-to-end cell therapy CDMO experience for our partners.”
Toshihisa Iida, Corporate Vice President and General Manager of Life Sciences Strategy Headquarters and Bio CDMO Division at FUJIFILM Corporation
According to the company, the organizational changes are intended to support increasing demand for cell therapy development, New Approach Methodologies (NAMs), and iPSC-based technologies. Fujifilm said the leadership structure will help advance its strategy of providing integrated support for cell-based research, therapeutic development, and contract manufacturing services in the United States.
